Genomeditech(Shanghai) Co.LTD

EN

EN

CN

Lentivirus

Cell Line Development

Protein Expression

Plasmid DNA Preparation Services

Adeno-associated Virus

Cell-based Assay

Antibody Services

Reporter Gene Detection Services

Plasmid

Stock Plasmid Reporter Plasmid Autophagy Fluorescent Single-Tag Plasmid Empty Vector Cell Tracking Plasmid iPS-Related Plasmids

Cell lines

Cytokines Immune checkpoints GPCR CLDN TAA Kinase TLR NK Antibody function Immunotherapy target In vivo imaging TNF LILR WNT Others Reference cells Antibody-related immune Recombinase Product integrin

Molecular Reference Standards

Reporter gene detection-related reagents

GMOne-Step GMOne-Step 2.0 GMBright One-Step GMSteady One-Step Dual Luciferase Reporter Gene Assay Kit D-Luciferin

Lentivirus

Overexpression Lentivirus Reporter Lentivirus In Vivo Imaging Lentivirus iPS-Related Lentivirus Immortalization Lentivirus Autophagy Lentivirus Cre Lentivirus Fluorescent Control Lentivirus

Proteins

Cytokines TAA Immune checkpoints Immunotherapy target GPCR TNF Kinase Others Antibody-related

Pseudovirus control material

Coronavirus-Like Pseudovirus Influenza-Like Pseudovirus Parainfluenza-Like Pseudovirus Respiratory Syncytial Virus-Like Pseudovirus Rhinovirus-Like Pseudovirus Human Metapneumovirus-Like Pseudovirus Monkeypox-Like Pseudovirus

Reagents related to cell function detection and analysis

GMTiter TM Luminescent Cell Viability Assay Cell Counting kit-8

Adeno-Associated Virus (AAV)

Optogenetics Chemical Genetics Calcium Imaging Cre Recombinase Standard Control Vectors

Antibodies

In Vivo MAb Antibodies ADC Antibody Loading Controls Antibodies & Tag Antibodies Biosimilar Antibodies Other Antibodies

Pseudovirus

SARS-CoV-2 pseudovirus Rabies Pseudovirus SARS Pseudovirus Influenza pseudovirus MERS pseudovirus HIV-1 Pseudovirus

Genoagent (Brand name of reagents)

lentiviral-packaging-tool Transfection Reagent Mycoplasma Removal Reagent Antibiotic Gene Knockout Kit Polybrene Switch-On Reagent Staphylococcal Enterotoxin E

News

Insights Resources

News

Insights

Resources

Current position：News > News

News

TfR1: Linking Iron Metabolism, Cancer, and Neurological Disorders

In 2025, a $12B acquisition put TfR1 in the spotlight, signaling huge potential in rare diseases, cancer, and neurological disorders.

Across multiple cutting-edge programs, TfR1 is opening doors to transformative therapies that could redefine patient care.

Accelerating Development of FOLR1 Target to Advance Multidimensional Cancer Therapy

Folate receptor alpha (FRα, FOLR1) is rapidly becoming one of the hottest targets in tumor therapy. With multiple antibody–drug conjugates (ADCs) now entering Phase III trials from global leaders like Eli Lilly and AstraZeneca, and emerging players such as Bio Thera and ProTarget Bio joining the race, competition around this target is intensifying.

From Elahere’s FDA approval to a new generation of FRα-directed ADCs, monoclonal antibodies, CAR-T therapies, and vaccines, the field is shifting from concept validation to clinical reality.

Dive into the full analysis to see how FRα is redefining the landscape of epithelial tumor treatment — and why it’s drawing worldwide attention from oncology innovators.

PD-1 × IL-2: A Combined Approach to Redefining Tumor Immunotherapy Strategies

While PD-1 inhibitors have transformed cancer treatment, their limits are becoming clear — and a new wave of innovation is rising. Cytokine engineering and PD-1 × IL-2 fusion therapies are redefining how we think about precision immune activation.

As PD-1 inhibitors reach their limits, the next frontier lies in cytokine engineering. Both Roche and Innovent Biologics are pursuing the PD-1 × IL-2v fusion strategy — yet with fundamentally different design philosophies.

TSHR: The Core Target in Thyroid Metabolic Regulation and Disease Therapy

The thyroid-stimulating hormone receptor (TSHR) is emerging as a key target in next-generation thyroid and autoimmune disease treatments. Once limited to hormone regulation, TSHR therapies now combine endocrine and immune pathways for greater precision and efficacy. With growing research and industry momentum, TSHR is shaping the future of smarter, more targeted thyroid therapies.

GM-C41979 Dual-Receptor Reporter Cell Line for PD-1–IL-2v Evaluation

Genomeditech has published a white paper on the GM-C41979 Dual-Receptor Reporter Cell Line, detailing its design, validation, and application for PD-1–IL-2v fusion protein evaluation. The report showcases how GM-C41979 integrates PD-1 and IL-2R signaling to provide a high-sensitivity, PD-1-dependent assay system. This publication demonstrates Genomeditech’s commitment to advancing reliable analytical tools for next-generation immuno-oncology drug development.

CDH17:Roche’s $1.45 Billion Licensing Deal with Hansoh Pharma Spotlights CDH17 ADC Innovation

FGFR: The Next Breakthrough Target in Cancer Treatment

FGFR2b is rapidly emerging as one of the most promising targets in oncology, driven by new clinical milestones and growing global investment in targeted and antibody-based therapies. Recent breakthroughs highlight how precision modulation of the FGFR pathway could reshape treatment strategies for epithelial tumors and beyond. As innovation accelerates, FGFR2b stands at the forefront of a new wave of cancer therapeutics—where biology, technology, and clinical insight converge.

GLP-1R: Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

FGF21: The Next Breakthrough in Metabolic Drugs?

In 2025, FGF21 has taken center stage in metabolic drug innovation.

GSK made headlines with a $2B deal for Boston Pharmaceuticals’ efimosfermin alfa. Just months later, Roche answered with its acquisition of 89bio and pegozafermin.

These billion-dollar moves signal a fierce race for FGF21—a once-monthly injectable with potential to regulate metabolism, cut liver fat, reduce inflammation, and reverse fibrosis.

Hailed as the successor to GLP-1, FGF21 is shaping up to be pharma’s next big breakthrough in obesity and metabolic disease.

2025 WCLC Witnesses: EGFR-Mutant NSCLC Enters the EGFR×HER3 Dual-Target Combination Era

Lung cancer treatment has seen major progress with the rise of targeted therapies, but many patients still face challenges when current options stop working. New scientific advances are now pointing to a different approach—using innovative dual-target and antibody-drug conjugate strategies to block cancer growth more effectively. These next-generation treatments are designed to tackle drug resistance and may offer patients longer-lasting benefits. Together, they signal an important step forward in the search for more reliable and durable solutions for people living with lung cancer.

First 1 2 3 4 5 Next Last

Total 6 Page

Jump

Current position：News > News

classify

News

TfR1: Linking Iron Metabolism, Cancer, and Neurological Disorders

In 2025, a $12B acquisition put TfR1 in the spotlight, signaling huge potential in rare diseases, cancer, and neurological disorders.

Across multiple cutting-edge programs, TfR1 is opening doors to transformative therapies that could redefine patient care.

Accelerating Development of FOLR1 Target to Advance Multidimensional Cancer Therapy

Folate receptor alpha (FRα, FOLR1) is rapidly becoming one of the hottest targets in tumor therapy. With multiple antibody–drug conjugates (ADCs) now entering Phase III trials from global leaders like Eli Lilly and AstraZeneca, and emerging players such as Bio Thera and ProTarget Bio joining the race, competition around this target is intensifying.

From Elahere’s FDA approval to a new generation of FRα-directed ADCs, monoclonal antibodies, CAR-T therapies, and vaccines, the field is shifting from concept validation to clinical reality.

Dive into the full analysis to see how FRα is redefining the landscape of epithelial tumor treatment — and why it’s drawing worldwide attention from oncology innovators.

PD-1 × IL-2: A Combined Approach to Redefining Tumor Immunotherapy Strategies

While PD-1 inhibitors have transformed cancer treatment, their limits are becoming clear — and a new wave of innovation is rising. Cytokine engineering and PD-1 × IL-2 fusion therapies are redefining how we think about precision immune activation.

As PD-1 inhibitors reach their limits, the next frontier lies in cytokine engineering. Both Roche and Innovent Biologics are pursuing the PD-1 × IL-2v fusion strategy — yet with fundamentally different design philosophies.

TSHR: The Core Target in Thyroid Metabolic Regulation and Disease Therapy

The thyroid-stimulating hormone receptor (TSHR) is emerging as a key target in next-generation thyroid and autoimmune disease treatments. Once limited to hormone regulation, TSHR therapies now combine endocrine and immune pathways for greater precision and efficacy. With growing research and industry momentum, TSHR is shaping the future of smarter, more targeted thyroid therapies.

GM-C41979 Dual-Receptor Reporter Cell Line for PD-1–IL-2v Evaluation

Genomeditech has published a white paper on the GM-C41979 Dual-Receptor Reporter Cell Line, detailing its design, validation, and application for PD-1–IL-2v fusion protein evaluation. The report showcases how GM-C41979 integrates PD-1 and IL-2R signaling to provide a high-sensitivity, PD-1-dependent assay system. This publication demonstrates Genomeditech’s commitment to advancing reliable analytical tools for next-generation immuno-oncology drug development.

CDH17:Roche’s $1.45 Billion Licensing Deal with Hansoh Pharma Spotlights CDH17 ADC Innovation

FGFR: The Next Breakthrough Target in Cancer Treatment

FGFR2b is rapidly emerging as one of the most promising targets in oncology, driven by new clinical milestones and growing global investment in targeted and antibody-based therapies. Recent breakthroughs highlight how precision modulation of the FGFR pathway could reshape treatment strategies for epithelial tumors and beyond. As innovation accelerates, FGFR2b stands at the forefront of a new wave of cancer therapeutics—where biology, technology, and clinical insight converge.

GLP-1R: Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

FGF21: The Next Breakthrough in Metabolic Drugs?

In 2025, FGF21 has taken center stage in metabolic drug innovation.

GSK made headlines with a $2B deal for Boston Pharmaceuticals’ efimosfermin alfa. Just months later, Roche answered with its acquisition of 89bio and pegozafermin.

These billion-dollar moves signal a fierce race for FGF21—a once-monthly injectable with potential to regulate metabolism, cut liver fat, reduce inflammation, and reverse fibrosis.

Hailed as the successor to GLP-1, FGF21 is shaping up to be pharma’s next big breakthrough in obesity and metabolic disease.

2025 WCLC Witnesses: EGFR-Mutant NSCLC Enters the EGFR×HER3 Dual-Target Combination Era

Lung cancer treatment has seen major progress with the rise of targeted therapies, but many patients still face challenges when current options stop working. New scientific advances are now pointing to a different approach—using innovative dual-target and antibody-drug conjugate strategies to block cancer growth more effectively. These next-generation treatments are designed to tackle drug resistance and may offer patients longer-lasting benefits. Together, they signal an important step forward in the search for more reliable and durable solutions for people living with lung cancer.

MORE

Message consultation

                    
Toll-free hotline：400-627-9288
                    
Email address：mkt.genomeditech@gmail.com

Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai

Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.

Message

Message consultation